NIH Begins First Clinical Trial Of Experimental Zika Vaccine

CNN: Human trials begin for Zika vaccines
“The National Institute of Allergy and Infectious Diseases has injected two human volunteers with an experimental DNA-based Zika vaccine, Director Anthony Fauci announced [Wednesday], a month ahead of its projected schedule for vaccine development…” (LaMotte, 8/3).

Reuters: U.S. health researchers test Zika vaccine as funds run low
“U.S. government researchers said on Wednesday they have begun their first clinical trial of a Zika vaccine while the Obama administration told lawmakers funds to fight the virus would run out in the coming weeks due to congressional inaction…” (Dunham, 8/3).

USA TODAY: National Institutes of Health launches first clinical trial of Zika vaccine
“…The NIH study began Tuesday, when the first volunteer was vaccinated. The vaccine will be tested in 80 healthy volunteers, ages 18 to 35, at three locations: the NIH Clinical Center in Bethesda, Md.; Emory University in Atlanta; and the University of Maryland in Baltimore, Fauci said…” (Szabo, 8/3).

Washington Post: NIH to begin testing Zika vaccine in humans
“…The main goal of the study will be to evaluate the vaccine’s safety and to see whether it generates an immune-system response in patients. If those early results are positive, researchers hope to began a larger-scale trial in Zika-affected countries in early 2017…” (Dennis, 8/3).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.